VerImmune is a biotech startup that operates in the cancer treatment market. The company is developing a novel therapy called Anti-Tumor Immune Redirection (AIR). This innovative treatment uses the body's immune memory, which is formed from childhood vaccines or past viral infections, to target and destroy cancer cells.

In simple terms, the AIR therapy makes tumor cells appear as if they are virally infected. This triggers the body's immune system, which has been trained by past vaccines or infections, to attack these cells. This approach leverages the patient's own immune system, potentially leading to a more effective and personalized cancer treatment.

VerImmune's business model revolves around the development and commercialization of this AIR therapy. The company's potential clients include cancer patients, healthcare providers, and insurance companies. The company aims to generate revenue through the sales of its therapy, once it has been approved by regulatory bodies.

The cancer treatment market is a large and growing one, with billions spent annually on cancer medicines and care. VerImmune's innovative approach could potentially disrupt this market, offering a new and potentially more effective treatment option for cancer patients.

Keywords: Biotech, Cancer Treatment, Anti-Tumor Immune Redirection (AIR), Immune Memory, Personalized Medicine, Healthcare, Cancer Care Market, Innovative Therapy, Immune System, Tumor Cell Death.